Tranexamic acid: Difference between revisions
m (Rossdonaldson1 moved page Tranexamic Acid to Tranexamic acid) |
No edit summary |
||
Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Action: Antifibrinolytic agent | *Action: Antifibrinolytic agent | ||
*Competitive inhibitor of plasminogen activation to plasmin | |||
*Dosing Availability: | *Dosing Availability: | ||
**Ampule of 1 Gm in 10 mL | **Ampule of 1 Gm in 10 mL |
Revision as of 20:52, 4 November 2015
Background
- Action: Antifibrinolytic agent
- Competitive inhibitor of plasminogen activation to plasmin
- Dosing Availability:
- Ampule of 1 Gm in 10 mL
Indication
Severely bleeding trauma patient, systolic blood pressure of <90 and/or heart rate > 110 beats/min., with expected requirement for massive transfusion.
Contraindication/Exclusion Criteria
- Greater than 3 hours from injury
- Known sensitivity to TXA
- Previous DVT or Pulmonary Embolism
Administration
Adult dose
Total of 2 Grams
- Initial bolus of 1 Gm over 10 minutes (Slow IV push). Draw up with filter needle.
- Maintenance: additional 1 Gm over next 8 hours (mix in 50 mL of NS). Call Pharmacy to mix and deliver the continuous infusion.[1]
Pediatric dose
Weight based
- Initial bolus of 20 mg/kg IV Bolus over 10 minutes
- Maintenance: 10 mL/kg/hr over next 8 hours
No additional laboratory tests required.
Adverse Reactions
- Thrombotic events
- Hypotension with rapid injection
- Nausea, vomiting, diarrhea
- Impaired color vision and other visual disturbances
See Also
External Links
Source
- ↑ CRASH-2 collaborators, Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y, Gando S, Guyatt G, Hunt BJ, Morales C, Perel P, Prieto-Merino D, Woolley T. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011 Mar 26;377(9771):1096-101,